Table 2.
treatment outcomes of small and large aneurysms before and after propensity score matching
| Variable | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| Max Diameter < 7.5 mm, N = 593 (66%)1 | Max Diameter ≥ 7.5 mm, N = 305 (34%)1 | P2 | Max Diameter < 7.5 mm, N = 302 (50%)1 | Max Diameter ≥ 7.5 mm, N = 302 (50%)1 | P2 | |
| WEB Device Type | 0.16 | 0.7 | ||||
| DL | 16 (2.8) | 14 (4.8) | 10 (3.5) | 13 (4.5) | ||
| SL | 492 (86) | 239 (82) | 234 (81) | 237 (82) | ||
| SLS | 64 (11) | 40 (14) | 45 (16) | 40 (14) | ||
| Access Route | 0.087 | 0.63 | ||||
| Femoral | 512 (86) | 254 (83) | 254 (84) | 253 (84) | ||
| Radial | 81 (14) | 49 (16) | 48 (16) | 47 (16) | ||
| Ulnar | 0 (0) | 2 (0.7) | 0 (0) | 2 (0.7) | ||
| Thromboembolic Complications | 21 (3.5) | 18 (5.9) | 0.1 | 12 (4.0) | 18 (6.0) | 0.26 |
| Timing of Thromboembolic Complications | 0.84 | 0.88 | ||||
| Intraop | 10 (48) | 8 (44) | 5 (42) | 8 (44) | ||
| Postop | 11 (52) | 10 (56) | 7 (58) | 10 (56) | ||
| Duration of Thromboembolic Complications | 0.71 | > 0.99 | ||||
| Permanent | 5 (38) | 5 (31) | 3 (33) | 5 (31) | ||
| Transient | 8 (62) | 11 (69) | 6 (67) | 11 (69) | ||
| Hemorrhagic Complications | 6 (1.1) | 6 (2.0) | 0.36 | 3 (1.0) | 6 (2.1) | 0.5 |
| Timing of Hemorrhagic Complications | 0.57 | 0.17 | ||||
| Intraop | 4 (67) | 2 (33) | 3 (100) | 2 (33) | ||
| Postop | 2 (33) | 4 (67) | 0 (0) | 4 (67) | ||
| Duration of Hemorrhagic Complications | > 0.99 | > 0.99 | ||||
| Permanent | 2 (33) | 2 (40) | 1 (33) | 2 (40) | ||
| Transient | 4 (67) | 3 (60) | 2 (67) | 3 (60) | ||
| Other Complications | 30 (5.9) | 19 (6.9) | 0.57 | 16 (6.0) | 19 (6.9) | 0.67 |
| Type of Other Complications | 0.9 | 0.82 | ||||
| Access site complication | 1 (4.5) | 1 (9.1) | 0 (0) | 1 (9.1) | ||
| Air embolus | 1 (4.5) | 0 (0) | ||||
| Contrast reaction | 2 (9.1) | 0 (0) | ||||
| Deployment issue | 7 (32) | 5 (45) | 5 (45) | 5 (45) | ||
| Groin Hematoma | 1 (4.5) | 1 (9.1) | 0 (0) | 1 (9.1) | ||
| Hematoma/Pseudoaneurysm | 10 (45) | 4 (36) | 6 (55) | 4 (36) | ||
| Duration of Other Complications | ||||||
| Transient | 11 (100) | 8 (100) | 6 (100) | 8 (100) | ||
| Antiplatelet Therapy | 520 (88) | 246 (81) | 0.004 | 266 (88) | 244 (81) | 0.017 |
| Last Clinical Follow-Up | 12 (5, 23) | 13 (6, 27) | 0.083 | 11 (5, 20) | 13 (6, 27) | 0.036 |
| Last Modified Rankin Scale | 0.2 | 0.18 | ||||
| 0 | 438 (80) | 220 (76) | 219 (79) | 218 (76) | ||
| 1 | 74 (13) | 39 (13) | 39 (14) | 39 (14) | ||
| 2 | 18 (3.3) | 10 (3.5) | 11 (4.0) | 10 (3.5) | ||
| 3 | 9 (1.6) | 7 (2.4) | 3 (1.1) | 7 (2.4) | ||
| 4 | 4 (0.7) | 2 (0.7) | 4 (1.4) | 2 (0.7) | ||
| 5 | 1 (0.2) | 1 (0.3) | 0 (0) | 1 (0.3) | ||
| 6 | 5 (0.9) | 10 (3.5) | 2 (0.7) | 10 (3.5) | ||
| Last mRS 0–1 | 512 (93) | 259 (90) | 0.065 | 258 (93) | 257 (90) | 0.17 |
| Last mRS 0–2 | 530 (97) | 269 (93) | 0.024 | 269 (97) | 267 (93) | 0.044 |
| Last mRS 6 (Mortality) | 5 (0.9) | 10 (3.5) | 0.008 | 2 (0.7) | 10 (3.5) | 0.023 |
| Last Imaging Follow-Up | 15 (6, 24) | 14 (6, 25) | 0.97 | 14 (6, 22) | 14 (6, 24) | 0.57 |
| Immediate Flow Stagnation | 505 (90) | 276 (92) | 0.34 | 265 (92) | 273 (92) | 0.92 |
| Immediate Raymond-Roy Classification | 0.004 | 0.17 | ||||
| 1 | 176 (31) | 60 (21) | 77 (27) | 60 (21) | ||
| 2 | 115 (20) | 69 (24) | 56 (20) | 68 (24) | ||
| 3 | 272 (48) | 162 (56) | 149 (53) | 160 (56) | ||
| Last Follow-Up Raymond-Roy Classification | < 0.001 | < 0.001 | ||||
| 1 | 317 (66) | 125 (47) | 168 (70) | 125 (48) | ||
| 2 | 114 (24) | 89 (34) | 48 (20) | 87 (33) | ||
| 3 | 46 (9.6) | 50 (19) | 25 (10) | 50 (19) | ||
| Adequate Occlusion (RR1 + RR2) | 431 (90) | 214 (81) | < 0.001 | 216 (90) | 212 (81) | 0.006 |
| Inadequate Occlusion (RR3) | 46 (9.6) | 50 (19) | < 0.001 | 25 (10) | 50 (19) | 0.006 |
| Compaction | 0.29 | 0.034 | ||||
| Same | 225 (59) | 122 (54) | 128 (65) | 122 (54) | ||
| Minor | 123 (32) | 75 (33) | 56 (28) | 73 (33) | ||
| Major | 35 (9.1) | 29 (13) | 13 (6.6) | 29 (13) | ||
| Major Compaction | 35 (9.1) | 29 (13) | 0.15 | 13 (6.6) | 29 (13) | 0.03 |
| Retreatment Required | 22 (3.7) | 37 (12) | < 0.001 | 11 (3.6) | 37 (12) | < 0.001 |
| Type of Retreatment | 0.047 | 0.013 | ||||
| Clipping | 2 (9.1) | 2 (5.4) | 0 (0) | 2 (5.4) | ||
| Coiling | 4 (18) | 6 (16) | 1 (9.1) | 6 (16) | ||
| Contour | 1 (4.5) | 0 (0) | ||||
| Endovascular techniques | 5 (23) | 1 (2.7) | 4 (36) | 1 (2.7) | ||
| FD | 4 (18) | 5 (14) | 3 (27) | 5 (14) | ||
| SAC | 5 (23) | 21 (57) | 2 (18) | 21 (57) | ||
| WEB | 1 (4.5) | 2 (5.4) | 1 (9.1) | 2 (5.4) | ||
1 n (%); Median (IQR)
2 Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test